At just 23, Josh McMillan has survived six life-threatening illnesses, including childhood leukaemia – but they’ve taken a toll that’s been more than just physical.
A revolutionary cancer drug developed in Auckland is set to begin clinical trials.
Tarloxotinib is designed to help patients with head and neck cancers for which New Zealand ranks as one of the highest in the world for cases.
Auckland City Hospital radiation oncologist Dr. Andrew Macann joined Mike Hosking.
Co-Director Prof. Andrew Shelling recently had the opportunity to tour the Integrated Cancer Centre in Spain and go to the European Association for Cancer Research (EACR) congress.
Waipapa Taumata Rau, University of Auckland launches Hīkina kia Tutuki Research Centres, focused on our most pressing challenges.
Lung cancer is the leading cause of cancer death in New Zealand with 1,700 deaths each year.
More New Zealanders die of lung cancer than of breast cancer, prostate cancer and melanoma combined.
Researchers at the Auckland Bioengineering Institute (ABI) aim to improve the health outcomes of those diagnosed with prostate cancer with a radical paradigm shift in radiotherapy treatment.
A Kiwi biotech company, started by our member Professor Rod Dunbar, is developing a new immunotherapy medicine that can help patients’ immune systems destroy cancer cells.
Distinguished Professor Dame Margaret Brimble wins a top chemistry award.
Our own Professor Cris Print recently spoke to RNZ about how it’s taken thousands of scientists decades to finish mapping the human genome. The Detail looks at why it’s taken so long and what it might mean for indigenous populations here in Aotearoa and around the world.
In this seminar we have Professor Stefan Bohlander speaking about Precision medicine for haematological malignancies. Why stamp collecting was important to understand AML.